Close Menu

NEW YORK – Calibre Scientific said this week that it has completed the acquisition of the NeXtal Biotechnologies line of structural biology products from Qiagen. NeXtal specializes in the production of unique screens and plates for protein crystallization, an important step in structural biology studies and structure-based drug design. NeXtal's products include a comprehensive suite of crystallization screens and proprietary EasyXtal crystallization plates that are currently sold in academic, biotechnology, and pharmaceutical markets.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.